[PDF] Top 20 El liderazgo transformacional en la gestión directiva de las instituciones educativas estatales del nivel secundaria

... Eligible patients who had already received metformin monotherapy entered a 2-week open-label run- in ...phase. Patients who received metformin plus one other antidiabetic therapy entered a 6-week washout ... See full document

... in patients aged 18 years with type 1 or type 2 diabetes and a documented clinical diagnosis of DME with proliferative or nonproliferative diabetic retinopathy and who, according to the ... See full document

... weeks. Patients in the aflibercept groups experienced average gains of + ...laser). Patients in the 2 mg PRN arm received a mean of ...and patients in the laser arm received a mean of ...Four ... See full document

... growing diabetic population. Linagliptin, a member of dipeptidyl peptidase-4 inhibitor class, is unique in its nonlinear pharmacokinetics with the characteristics of rapid attainment of steady state, little ... See full document

... history-taking. Patients should be queried at the time of an office visit as to whether they are experiencing tingling, burning, or pain at rest in their ... See full document

... and patients received vandetanib at a daily dose of 300 mg until progression of disease, withdrawal of consent, or unacceptable ...and tolerability, as well as changes in serum levels of calcitonin and the ... See full document

... endoscopy. Patients were told to take the wireless data receiver in the pockets or bags, with the distance no more than 2 meters at any time during recording ...period. Patients were encouraged to keep nor- ... See full document

... non- diabetic mice after vascular injury ...markers. Linagliptin is soluble in lipids, so it might be predisposed to lipid ...upon linagliptin treatment ...upon linagliptin treatment in the ... See full document

... and clinical trials are designed to determine the efficacy of an intervention, or the benefit of that intervention under ideal ...Well-designed clinical trials are costly, time-consuming, and may over-state ... See full document

... MM patients with median 5 prior lines of therapy (range: 1 – ...The patients received selinexor at two different dose levels, once or twice weekly, ixazomib on days 1,8,15 and dexamethasone on the days of ... See full document

... of diabetic ketoacidosis (DKA), the so-called euglycemic DKA, which is de fi ned as DKA without marked hypergly- ...no clinical consequences but was signi fi cantly associated with improved insulin ...some ... See full document

... of patients with epilepsy continue to have seizures despite current treatments, indicating the need for better antiseizure medications with novel mechanisms of ...adult patients with ...of patients ... See full document

... many patients to discontinue their ...the patients administered 800 mg ...the tolerability of patients who show muscle toxicity after the administration of ... See full document

... of patients most likely to show unintended therapeutic side effects, and prediction of patient outcome in both clinical trials and daily clinical ...human patients also have the potential to ... See full document

... Genomic DNA was extracted from patients’ peripheral blood leukocytes. Polymerase chain reaction (PCR) and Sanger sequencing were performed to identify PRRT2 mutations, and no attempt was made to screen other ... See full document

... in clinical laboratory data (representing the tolerability index) during the observation period are shown in Table ...other tolerability index showed no statistical difference at baseline com- pared ... See full document

... TCD can also be used to monitor the efficacy of treatment with intravenous recombinant tissue plasminogen activator (rtPA) for acute ischemic stroke, and is the only tool that can monitor thrombolysis-induced reperfusion ... See full document

... an incidence of TEAEs similar to that seen in cycle 1. The incidence of TEAEs did not increase with increasing cycles of chemotherapy, and cumulative toxicity was not evident. In an integrated safety analysis of the ... See full document

... 4071) patients continuously refilled their medication throughout the course of the year, as compared to 9% of bimatoprost (n = 1199) patients and 5% of travoprost (n = 1001) ... See full document

... thirty-seven patients (672 eyes) affected by primary open-angle glaucoma and intraocular hypertension were recruited over a period of 10 years from the Glaucoma Centre, Department of Ophthalmological Sciences, ... See full document